Percentage and number in 1000s of total catastrophic health costs cases averted by vaccines in 41 low-income and middle-income countries for those born between 2016 and 2030
| (1) | (2) | (3) | |
| Measles vaccine (95% UR) | Pneumococcal conjugate vaccine (95% UR) | Rotavirus vaccine (95% UR) | |
| Current coverage trends | |||
| Lowest | 75.2% (69.6–80.8) | 22.2% (15.8–28.8) | 40.4% (29.6–51.1) |
| 12 506 (10 636–14 409) | 38 (26–51) | 47 (31–64) | |
| 2nd quintile | 19.9% (14.3–25.4) | 21.7% (15.2–28.7) | 30.3% (19.7–40.7) |
| 3286 (2290–4268) | 37 (24–50) | 36 (21–49) | |
| 3rd quintile | 4.7% (3.1–6.5) | 18.4% (12.6–25.3) | 19.6% (11.3–27.8) |
| 779 (501–1045) | 32 (20–44) | 22 (12–34) | |
| 4th quintile | 0.1% (0.1–0.2) | 20.2% (14.0–26.3) | 9.4% (3.9–15.5) |
| 19 (10–29) | 34 (23–46) | 11 (4–18) | |
| Highest | 0.0% (0.0–0.0) | 17.4% (11.6–23.1) | 0.0% (0.0–1.6) |
| 0 (0–1) | 30 (18–40) | 0 (0–2) | |
| Best case | |||
| Lowest | 75.2% (69.7–80.8) | 24.7% (22.1–27.2) | 57.4% (53.1–61.3) |
| 13 097 (11 110–15 108) | 495 (438–558) | 536 (469–604) | |
| 2nd quintile | 19.9% (14.2–25.3) | 20.7% (18.5–22.9) | 20.4% (17.6–23.4) |
| 3442 (2384–4472) | 416 (366–465) | 190 (161–220) | |
| 3rd quintile | 4.8% (3.1–6.6) | 19.6% (17.3–21.7) | 14.8% (12.3–17.5) |
| 826 (532–1106) | 394 (346–442) | 138 (114–162) | |
| 4th quintile | 0.1% (0.1–0.2) | 17.7% (15.7–19.6) | 6.2% (4.7–7.8) |
| 20 (11–30) | 354 (312–394) | 57 (44–72) | |
| Highest | 0.0% (0.0–0.0) | 17.5% (15.5–19.3) | 1.2% (0.6–1.9) |
| 0 (0–1) | 351 (309–391) | 10 (6–17) | |
Note. Current coverage trends represent current vaccination forecasts. Best case includes additional Gavi funding for the expansion or implementation of vaccines. Figures present the average value of cases by economic quintile with 95% URs.
95% URs are given in parentheses.
UR, uncertainty range.